1. Home
  2. AVPT vs HROW Comparison

AVPT vs HROW Comparison

Compare AVPT & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AvePoint Inc.

AVPT

AvePoint Inc.

HOLD

Current Price

$13.02

Market Cap

2.0B

Sector

Technology

ML Signal

HOLD

HROW

Harrow Inc.

HOLD

Current Price

$33.25

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AVPT
HROW
Founded
2001
1998
Country
United States
United States
Employees
3443
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.7B
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
AVPT
HROW
Price
$13.02
$33.25
Analyst Decision
Buy
Strong Buy
Analyst Count
12
8
Target Price
$16.64
★ $69.86
AVG Volume (30 Days)
★ 1.4M
487.9K
Earning Date
05-07-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 71.43
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$25.00
$31.62
Revenue Next Year
$19.63
$50.77
P/E Ratio
$1,348.94
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.84
$28.54
52 Week High
$15.58
$54.98

Technical Indicators

Market Signals
Indicator
AVPT
HROW
Relative Strength Index (RSI) 46.61 35.19
Support Level $12.82 $32.46
Resistance Level $13.91 $36.37
Average True Range (ATR) 0.42 1.33
MACD -0.05 -0.10
Stochastic Oscillator 32.32 20.66

Price Performance

Historical Comparison
AVPT
HROW

About AVPT AvePoint Inc.

AvePoint Inc is a provider of modern data protection, enabling organizations to secure, govern, and operationalize data at scale across cloud ecosystems. Customers rely on the AvePoint Confidence Platform to reduce risk, improve operational efficiency, and accelerate digital transformation as it adopt cloud collaboration and artificial intelligence (AI)-driven developed tools and workflows. Its products and services are sold throughout the world, through direct and indirect sales channels.

About HROW Harrow Inc.

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.

Share on Social Networks: